Immune regulation by the peripheral lymphatics and its implications for wound healing and infection control in lymphoedema

Hancock DG, Potezny TM & White PM

ABSTRACT

Lymphoedema is a complex disorder with high disease morbidity characterised initially by progressive fluid accumulation and subsequently by altered tissue fibrosis and fat deposition. Primary lymphoedema is the result of congenital conditions that affect how lymph vessels are formed, whilst the inciting event in secondary lymphoedema is classically the disruption of normal lymphatic flow in the context of surgery or trauma. In addition to the altered fluid and fat homeostasis, lymphoedema is characterised by immune deficits that typically manifest as an increased susceptibility to infection and altered wound healing in the affected site. In contrast to the common perception of the lymphatics as a passive conduit for fluid, waste products, and immune cells, the altered immune homeostasis in lymphoedema patients suggests that the lymphatics play a more active role in the immune response. Indeed, lymphatic dysfunction appears to be a global phenomenon in all immune-related diseases. In this review, we highlight papers that support an active role for the lymphatics in immunity and link this evidence to the observed deficits in wound healing and immune surveillance present in lymphoedema.

Keywords: Lymphoedema, lymphatics, immunity, wound healing.

INTRODUCTION

The peripheral lymphatic system is made up of a complex network of lymphatic vessels that connect local tissue sites with secondary lymphoid organs. The peripheral lymphatics play an essential role in the regulation of fluid balance, in the transport of fatty acids from the gastrointestinal tract, and the trafficking of immune cells to and from the periphery. Specifically, the transport of dendritic cells to lymphoid organs for the generation of adaptive immune responses and the drainage of local immune mediators for the maintenance of local immune homeostasis have been the primary immune roles of the lymphatic system described to date.

Alterations in the peripheral lymphatics, as is seen with specific genetic deficiencies or peripheral lymphatic destruction, can lead to primary and secondary lymphoedema, respectively. Lymphoedema was originally considered a circulatory condition characterised initially by abnormal fluid distribution, with the progression to fat deposition/fibrosis in its later stages. However, there is also evidence of concurrent immune dysfunction in lymphoedema, suggesting that lymphoedema could also be classified as a functional immune disorder. The immune dysfunction present in lymphoedema typically manifests in excessive fibrosis, local inflammation, poor wound healing, and an increased susceptibility to infections and new malignancies. Indeed, these consequences are a major contributor to the extremely high disease morbidity and poor quality of life consistently observed in patients with lymphoedema as well as being the primary reason for hospitalisation in this patient population.

However, the mechanisms leading to the immune deficits in lymphoedema remain poorly understood. While the role of the peripheral lymphatic system in immune trafficking is well described, it may be that the lymphatics play additional roles...
in regulating the phenotype and function of local immune populations.

While the incidence of lymphoedema is relatively low, the insights gained from understanding the progression from primary lymphatic disruption to the observed patterns of altered immune homeostasis has important consequences for progressing our understanding of the complexity of immunological disease in humans. Indeed, *de novo* lymphangiogenesis, the formation of new lymphatic vessels, has been identified in the majority of human inflammatory conditions, including psoriasis, renal inflammation, and chronic airway inflammation. In addition to the production of new lymphatic vessels, the phenotype of the lymphatic vessels present can also be altered as compared to controls, suggesting altered lymphatic function contributes to the pathogenesis of these diseases. Finally, peripheral lymphatic vessels also play key roles in transplant rejection and tumour metastases. Therefore, it appears clear that lymphatic function has strong implications for a wide range of immune-based conditions, supporting evidence of an active role of the lymphatics in immunity.

In this review, we attempt to consolidate the evidence surrounding lymphatic-mediated immune responses to provide mechanistic insights into the progression from disrupted lymphatic vessel flow to altered wound healing and immune clearance in lymphoedema.

**LYMPHATIC REGULATION OF THE IMMUNE RESPONSE**

The peripheral lymphatics system has been implicated in the regulation of immune cell migration and activation, as well as the clearance of local immune mediators and waste products from the effector sites, all of which are influenced by *de novo* lymphangiogenesis. While these functions have been described in a number of primarily *in vitro* or model organism studies, there remains a lack of strong mechanistic links between these functions and the observed immune deficits in lymphoedema or other immune conditions with lymphatic involvement.

**Regulation of cellular migration**

The migration of dendritic cells from an infected tissue site to the draining lymph node is the essential first step in the initiation of T cell and B cell responses to peripheral infections. Thus, the lymphatics role in modulating the migration and function of dendritic cells has important consequences for adaptive immunity.

In response to inflammation, dendritic cells are known to upregulate the expression of a range of different chemokine receptors and integrins, which facilitate their migration through the lymphatics to the draining lymph nodes. The most prominent molecules involved in dendritic cell migration through the lymphatics appear to be the chemokine receptor CCR7 (recognising lymphatic expressed CCL21) and the integrin LFA-1 (recognising lymphatic expressed ICAM-1), although a number of other molecules have been implicated. However, given that the lymphatics have been shown to upregulate the expression of the chemokine CCL21 and integrin ICAM-1 in response to the same infectious signals that induce the expression of their partner molecules on dendritic cells, the activation programs of both dendritic cells and the lymphatics appear inseparable and equally important in this initiation step for adaptive immunity. In further support of the active role the lymphatics play in this process, lymphatic activation can induce the structural reorganisation and formation of ICAM-1 enriched microvilli structures, which optimise dendritic cell attachment and migration.

While, the CCL21-CCR7 axis has been strongly linked with dendritic cell migration through the lymphatics, it is also important to note that CCL21 is an important chemoattractant for recruiting local macrophages to sites of inflammation (without inducing their migration through the lymphatics to the draining lymph nodes). Given that T cells and neutrophils can also traffic through the peripheral lymphatics system and migrate in response to chemokine gradients, the lymphatics likely play a similar active role in inducing the migration and local recruitment of these local cell populations. For example, various T cell subsets also express CCR7 and thus their migration or local recruitment is likely to be influenced by lymphatic expressed CCL21.

**Regulation of cellular activation**

While the role of the lymphatics system in regulating cell migration is well established, there is strong circumstantial evidence to suggest an additional role in regulating cellular activation. However, these mechanisms have largely not been confirmed *in vivo* and as such the relative importance of this lymphatic function remains unclear.

While playing a primary role in inducing cellular migration, it is important to note that chemokine and integrin signalling additionally acts to induce cell activation. For example, mice deficient in CCL21 (which signals through the chemokine receptor CCR7), not only show deficits in dendritic cell migration, but important additional defects in dendritic cell maturation, proliferation, differentiation, endocytosis function and overall survival. Similarly, lymphatic expressed ICAM-1 (which signals through the integrin partner LFA-1) has been shown to downregulate dendritic cell expression of CD86 and other maturation markers, which in turn reduces the dendritic cell’s ability to activate T cell responses. Thus cell migration and activation are clearly linked, and as such, the lymphatics are clearly important regulators of this process.

In addition to the expression of molecules involved in cellular migration, the lymphatics can also express a wide range of poly-functional pro-inflammatory and anti-inflammatory molecules. For example, lipopolysaccharide has been
shown to induce the expression of IL-6 in lymphatic endothelial cells in vitro. IL-6 is an extremely important immune regulator that has been shown to regulate the activation and effector function of neutrophils, macrophages, and dendritic cells, among a range of other functions. In addition, IL-6 has been clearly shown to contribute to the autoimmune driven inflammation in disease like rheumatoid arthritis, and as such has been successfully targeted with the IL-6R antibody, Tocilizumab. While a large number of immune cell populations have been shown to express IL-6 including fibroblasts, macrophages, neutrophils, and T-cells, the observation of lymphatic IL-6 expression strongly suggests that the lymphatics are contributing to immune cell activation and the progression of the immune response. Indeed, this mechanism of immune regulation can be extended to a large number of other immune mediators that the lymphatics express in response to stimulation.

Regulation of Immune Homeostasis through Soluble Mediators and Antigen

As the primary conduit system draining fluid and waste tissues from peripheral sites, the lymphatics play an important role in maintaining the homeostasis of these factors. While the production of cytokines and chemokines (produced by both lymphatic endothelial cells and other immune populations) shape and direct the local immune response, the removal of these mediators is equally important for preventing chronic inflammation or aberrant signalling pathways.

The lymphatics are also involved in the active removal of cytokines and chemokines from circulation via the expression of scavenger receptors like D6, which internalise chemokines and pro-inflammatory cytokines. Importantly, mice deficient in the scavenger receptor D6, showed grossly exaggerated inflammatory responses at local sites and altered patterns of immune cell migration and recruitment, a general pattern sharing some similarities with the immune deficits in lymphoedema.

Finally, the passive transport of antigen to the secondary lymphoid organs is important for maintaining self-tolerance (to self-antigens only expressed in the periphery) or generating immune responses (to pathogenic antigens), separate from the dendritic cell-mediated transport of these antigens.

Regulation of Immune Homeostasis through Lymphangiogenesis

De novo lymphangiogenesis appears to be a critical step in many inflammatory contexts for promoting fluid drainage and immune cell migration from the site of inflammation, and as such is frequently observed in human disease. Lymphangiogenesis is classically induced by the canonical vascular endothelial growth factors (VEGFs)-A, -C, and -D. Importantly, these VEGF molecules are commonly produced by activated macrophages, T cells, mast cells, and dendritic cells in response to a diverse range of immunogenic stimuli, which provides a clear explanation for the observed changes in lymphangiogenesis in the majority of human immune-mediated diseases. Furthermore, lymphangiogenesis can also be induced by a range of secondary immune mediators (for example, IL-10, TFGβ) either directly or indirectly via the upregulation of VEGF expression by other immune cells. Similarly, lymphangiogenesis can also be negatively regulated by immune mediators, including the Th2 cytokines IL-4 and IL-13.

Most importantly, lymphangiogenesis is not always associated with favourable outcome, as the pathogenesis of ocular inflammation, transplant rejection, and tumour metastasis are often driven by undesired lymphangiogenesis. Furthermore, it has been suggested that chronic inflammation can drive a disordered process of lymphangiogenesis, which actually impairs immune cell migration and fluid drainage when compared to the structured process of lymphangiogenesis in an appropriate inflammatory response.

STIMULUS-SPECIFIC LYMPHATIC ACTIVATION

The immune system allows for appropriate responses to distinct pathogens through the generation of stimulus-specific effector programs, such as the classical division between Th1 versus Th2 versus Th17 T cell responses. A given immune response is established through the integration of primary (to pathogens) and secondary (to immune cytokines/chemokines) activation signals. It is the capacity of these immune cells to generate the appropriate stimulus-specific response that determines whether the immune response effectively controls the pathogen or results in the development of an inappropriate response leading to chronic inflammation or autoimmunity. Thus to be considered an active regulator of the immune response, the lymphatics need to generate stimulus-specific effector programs in response to distinct stimuli.

Lymphatic endothelial cells express functional toll-like receptors (TLRs) 1–6 and 9 and can thus respond to a range of pathogenic stimuli including lipopolysaccharide (LPS) (via TLR4) or lipoteichoic acid (via TLR2); both major constituents of the bacterial cell wall. Most importantly, as with other cell populations distinct patterns of cytokines and chemokines are induced when lymphatic endothelial cells are stimulated in vitro with different TLR ligands. For example, lipopolysaccharide (signalling via TLR4) induced the upregulated expression of the chemokine CCL20 in lymphatic endothelial cells in vitro, while stimulation with heat-killed Listeria monocytogenes (signalling primarily through TLR2) did not.

Consistent with their response to a number of diverse pathogenic stimuli, lymphatic endothelial cells can also respond to a number of key immune mediators including adrenomedullin, chemokine (C-X-C Motif) ligand 12 (CXCL12), high-mobility group box 1 (HMGB1), histamine, hypoxia inducible factor-alpha (HIF-1α), interferon alpha (IFNα), IFNβ, IFNγ, IL-1β, IL-4, IL-6, IL-8, IL-13, IL-20, IL-27, oncostatin...
M, retinoic acids, thrombin, transforming growth factor beta (TGFβ), and tumour necrosis factor alpha (TNFα)\textsuperscript{18,37,45-60}. Importantly, the responses to these secondary activation signals also appear to be stimulus-specific. One paper described unique effector responses observed to TNFα, IL-1β, or IFNγ stimulation in vitro, including the selective upregulation of the cell adhesion molecule E-selectin, in response to stimulation with IFNγ, but not to stimulation with TNFα or IL-1β\textsuperscript{47}. Consistent with the pathogen-specific regulation of CCL20, lymphatic endothelial cell stimulation with TNFα or oncostatin M also induced the expression of CCL20 in vitro, while stimulation with IL-1β did not\textsuperscript{10}.

This stimulus-dependent specificity is also observed in more physiological models of inflammation. For example, large differences in the transcriptional expression of key chemokines and integrins were observed in lymphatic endothelial cells isolated from a mouse model of oxazolone-induced contact hypersensitivity versus a mouse model of Complete Freund’s Adjuvant-induced inflammation\textsuperscript{61}. Given the diverse immunoregulatory roles of the lymphatics (as discussed above), it seems likely that the different lymphatic activation programs in these two models is at least partially contributing to the gross differences in inflammation, cell activation/migration, and levels of oedema additionally observed in these models\textsuperscript{61}. However, the relative contribution of the lymphatics to these differences, as compared to the effect of other cell populations (for example, macrophages) that are differentially activated in these two models is difficult to assess.

It should also be noted that over 1000 genes were differentially expressed in the inflammation-activated lymphatics in these models\textsuperscript{61}. Given that we have only established the relevance of a few chemokines and adhesion molecules in this list, these results strongly highlight our relatively poor understanding of lymphatic function.

### CLINICAL SIGNIFICANCE OF LYMPHATIC FUNCTION

While a number of diverse immune functions have been suggested for the peripheral lymphatics (as discussed above), the majority of these studies have been performed in model systems and their importance in clinical disease is less clear. However, there is strong indirect evidence to suggest that the in vitro observations of lymphatic immune function are relevant in vivo.

In a study that compared gene expression in lymphatic endothelial cells isolated from lymphoedema skin and normal controls, over 2500 genes were found to be differentially regulated, including important pro-inflammatory genes IL-6, IL-8, and IL-32\textsuperscript{14}. It should be noted that this study would have ideally compared gene expression in lymphoedema to gene expression in ‘normal’ inflammation, in order to better assess which genes were specifically dysregulated in response to the unique inflammatory context of lymphoedema. Lymphatic filariasis (also known as elephantiasis) is a tropical disease caused by the filarial parasites \textit{Wuchereria bancrofti} (90% of cases), \textit{Brugia malayi}, and \textit{Brugia timori} that presents with a clinical picture remarkably similar to lymphoedema\textsuperscript{62}. In a gene expression study assessing the effects of lymphatic endothelial cell stimulation with \textit{Brugia malayi}, key immunological molecules related to lymphangeogenesis and immune cell migration/activation were shown to be differentially expressed as compared to controls\textsuperscript{14}. Finally, a large number of differentially expressed genes have been observed in a study assessing lymphatic endothelial cell gene expression in type 2 diabetic patients, whose deficits in wound healing and immunity share some characteristics with those in lymphoedema patients\textsuperscript{63}. Thus, these three gene expression studies all showed the differential expression of a large number of immune-related genes in different contexts where there is known lymphatic and immune dysfunction. While not directly assessed, when considered in the context of the in vitro studies (as discussed above), these results imply that the altered pattern of immune molecule expression is contributing to the altered immune homeostasis in a clinical context.

Alterations in the lymphatics system, especially in the phenotype of lymphatic vessels and in patterns of \textit{de novo} lymphangio genesis, have also been observed in the majority of human immune diseases\textsuperscript{6-9}. As an example, the autoimmune, inflammatory skin condition psoriasis is characterised by a number of changes in the peripheral lymphatics system that together imply a role for the lymphatics in the pathogenesis of this disease. The immune pathogenesis in psoriasis is not fully understood, but thought to be driven by T cells polarised towards a Th-1 or Th-17 phenotype\textsuperscript{64,65}. Interestingly, the lymphatics have been shown to be able to regulate their expression of key immune mediators in a stimulus-specific manner in response to the majority of cytokines that have been implicated in the pathogenesis of psoriasis\textsuperscript{4,66}, including IL-27\textsuperscript{4} or TNFα\textsuperscript{47}. In addition, increased tissue levels of VEGF, with corresponding increases in lymphatic vessel density, have been frequently observed in the skin of psoriasis patients\textsuperscript{32,66}. Finally, in a mouse model of psoriasis, systemic VEGF blockade significantly improved the levels of inflammation, further implying a direct immunoregulatory role for the lymphatics\textsuperscript{67}. Thus, while these mechanisms have not been conclusively established, these results strongly suggest that the lymphatics are in fact playing an important role in psoriasis and related immune-mediated conditions.

### LINKING LYMPHATIC DAMAGE TO THE IMMUNE PATHOGENESIS OF LYMPHOEDEMA

Secondary lymphoedema is generally initiated by local lymphatic damage following radiation or surgery, but results in a number of global immune deficits, including defects in immune surveillance (susceptibility to infection and malignancy) and local immune homeostasis (abnormal fibrosis, inflammation, and wound healing)\textsuperscript{3,4}. While these immune deficits are commonly observed in lymphoedema...
patients, the mechanisms of disease progression following an initial lymphatic insult are poorly understood. However, the active immune roles of the peripheral lymphatics (as discussed in this review) may provide an insight into the pathogenesis of lymphoedema (Figure 1).

The primary result of lymphatic vessel damage following interventions like surgery or radiotherapy is a gross reduction in drainage function. This results in the local accumulation of fluid, waste products, immune mediators (cytokines and chemokines), and immune cells that are unable to effectively transit to lymphoid organs. The irregular build up of these molecules appears to be the initiating factor driving the altered activation programs in the lymphatic endothelial cells and in other immune cell populations (for example, macrophages) observed in lymphoedema and chronic inflammation\textsuperscript{14,61}. However, given that the lymphatics are known to respond to immune mediators produced by macrophages (including TNF\textsubscript{α}, IL-1\textsubscript{β}, and IFN\textsubscript{γ})\textsuperscript{47} and produce immune mediators that regulate the function of macrophages (including IL-6 and CCL21)\textsuperscript{12}, it is likely that abnormal lymphatic activation perpetuates the abnormal activation of macrophages, and visa versa. Indeed, while the accumulation of these molecules may initially result in an excessive, but otherwise normal, pattern of inflammation, it is likely that prolonged exposure and persistent immune cell activation results in the disordered and abnormal inflammation characteristic of lymphoedema.

Given that both macrophages and the lymphatics system have been critically implicated in the normal wound healing process\textsuperscript{68-71}, it is not surprising that wound healing is severely compromised in the grossly abnormal immune microenvironment of lymphoedema\textsuperscript{72,73}. Specifically, IL-10 and TGF\textsubscript{β} have both been linked to the abnormal wound healing observed in lymphoedema and both have been shown to modulate the phenotype and function of both macrophages and lymphatic endothelial cells\textsuperscript{50,74,75}. Similarly, abnormal lymphatic endothelial cell activation and subsequent abnormal modulation of dendritic cell function, coupled with gross defects in the ability of dendritic cells to migrate to lymphoid organs through the disrupted lymphatics, likely explains the increased susceptibility to infection in lymphoedema.
CONCLUSIONS

This review has focused on highlighting the lymphatics as an active and integrated component of the immune response. While the initiating process in secondary lymphoedema may be disruption of lymphatic flow and the accumulation of fluid, waste products, and immune mediators, these initial processes are likely to drive a dysregulated cycle of abnormal lymphatic and immune cell activation, that affects the normal capacity of these cells to mediate wound healing and immune clearance.

REFERENCES


REDUCTION IN CHRONIC WOUND PAIN
REDUCTION OF BACTERIAL BURDEN

KENDALL™ AMD
ANTIMICROBIAL FOAM DRESSINGS
WITH PHMB (POLYHEXAMETHYLENE BIGUANIDE HCl)

Results of the trial suggests PHMB impregnated foam dressing as a viable option for the treatment of critically colonised chronic wounds.